Inhibitors of Bruton’s Tyrosine Kinase (BTK) have proven to be efficacious in treating CLL via interrupting BCR signaling as well as the supportive cell:cell interactions within the lymphoid tissue microenvironment (11). Here, BTK is linked to B-cell chronic lymphocytic leukemia.